Lenalidomide capsules, a generic version of the popular multiple myeloma drug Revlimid, have been introduced to the US market, according to pharma giant Dr Reddy’s Laboratories, which on Wednesday informed the stock markets.
According to Dr. Reddy’s, with this volume-restricted launch, two (2.5 mg and 20 mg) out of the six strengths it has introduced for the medicine in the US market are qualified for first to market, 180 days of generic drug exclusivity.
The company launched the cancer medication in the US in the following strengths: 2.5 mg, 5 mg, and 10 mg, each in a bottle count size of 28 capsules; 15 mg, 20 mg, and 25 mg, each in a bottle count size of 21.
In September 2020, Dr. Reddy’s and Celgene, a fully owned subsidiary of BMS, reached a patent settlement for Revlimid, a drug with annual sales of around $12.80 billion USD. In settlement of all unresolved claims in its litigation, “Celgene agreed to provide Dr Reddy’s a licence to sell volume limited amounts of generic lenalidomide capsules in the US,” Dr Reddy’s stated.